Related Experiment Videos
Apoptosis in neuroendocrine tumours
1Center for Molecular Medicine, School of Medicine, University of Connecticut Health Center, Farmington CT 06030-3101, USA. dwang@nso2.uchc.edu
Clinical Endocrinology
|September 1, 1999
Summary
Neuroendocrine tumors (NETs) resist apoptosis, promoting cancer growth and chemoresistance. Targeting programmed cell death pathways offers potential for new NET treatments.
Area of Science:
- Oncology
- Molecular Biology
- Cancer Research
Background:
- Acquired resistance to apoptosis contributes to neuroendocrine tumor (NET) clonal expansion and persistence.
- Deregulation of programmed cell death is critical in NET multistep tumorigenesis.
- Frequent Bcl-2 oncoprotein expression in NETs may play a role in their pathogenesis.
Purpose of the Study:
- To investigate the role of apoptosis resistance in neuroendocrine tumor development.
- To explore the potential link between Bcl-2, c-Myc, and NET multistep tumorigenesis.
- To understand how oncogenes influence cell death rates in cancer biology.
Main Methods:
- Analysis of apoptosis resistance mechanisms in NETs.
- Investigation of Bcl-2 and c-Myc genetic complementation in NETs.
- Correlation of apoptosis resistance with chemoresistance in NETs.
Main Results:
- Apoptosis resistance in NETs facilitates clonal expansion and tumor growth.
- Simultaneous deregulation of Bcl-2 and c-Myc may be implicated in human NET tumorigenesis.
- Apoptosis resistance typically correlates with chemoresistance in NETs.
Conclusions:
- Understanding apoptosis deregulation in NETs is crucial for pathogenesis.
- Targeting programmed cell death pathways may lead to more effective NET treatments.
- Inducing programmed cell death could be an integral component of curative NET therapies.